Cisplatin and paclitaxel for non-small-cell lung cancer: The European experience

Many physicians have questioned whether the additional survival benefit gained from the use of combination chemotherapy in non-small-cell lung cancel has been offset by chemotherapy-induced toxicity, particularly with cisplatin (Platinol). However, the impressive efficacy of paclitaxel (Taxol) (1-year survival > 40%) made its combination with cisplatin logical, When compared to older standard regimens (eg, cisplatin and teniposide [Vumon]) paclitaxel and cisplatin resulted in significantly higher response rates but comparable survival rates at 1 and 2 years. The paclitaxel and cisplatin regimen was better tolerated. Further studies are required to evaluate the combination of paclitaxel with newer agents to reduce toxicity and develop simple, outpatient regimens.